Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2005 Oct 25;93(10):1144–1151. doi: 10.1038/sj.bjc.6602845

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2005 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Uptake of [¹⁷⁷Lu-DOTA⁰-Tyr³]-octreotate was studied in tumours as well as in several organs 24 h p.i. In the tumours, the maximum uptake was 17±3.3%IA g⁻¹ (mean±s.e.m. n=5 for all groups) and was seen in animals receiving 15 MBq (0.5 μg) and 7.5 MBq (0.25 μg) [¹⁷⁷Lu-DOTA⁰-Tyr³]-octreotate. Decreasing uptake for higher administered doses indicated saturation of sstr in tumour tissue. For the critical organs kidney and liver, no signs of saturation was seen. P-values reflect the difference vs 7.5 MBq.